Page last updated: 2024-12-06

medroxalol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

medroxalol: RN given refers to parent cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID41835
CHEMBL ID113278
CHEBI ID135571
SCHEMBL ID120537
MeSH IDM0083618

Synonyms (35)

Synonym
rmi 81968
rmi 81,968
nsc313453
D04888
medroxalol (usan/inn)
56290-94-9
OPREA1_438410
rmi-81968
medroxalol
einecs 260-099-3
benzamide, 5-(2-((3-(1,3-benzodioxol-5-yl)-1-methylpropyl)amino)-1-hydroxyethyl)-2-hydroxy-
5-(2-((3-(1,3-benzodioxol-5-yl)-1-methylpropyl)amino)-1-hydroxyethyl)salicylamide
medroxalolum [inn-latin]
5-(1-hydroxy-2-((1-methyl-3-(3,4-(methylenedioxy)phenyl)propyl)amino)ethyl)salicylamide
CHEBI:135571
5-[2-[4-(1,3-benzodioxol-5-yl)butan-2-ylamino]-1-hydroxyethyl]-2-hydroxybenzamide
rmi-81,968
CHEMBL113278
medroxalolum
medroxalol [usan:inn:ban]
7px96289ja ,
unii-7px96289ja
medroxalol [usan]
5-[1-hydroxy-2-[[1-methyl-3-[3,4-(methylenedioxy)phenyl]propyl]amino]ethyl]salicylamide
medroxalol [inn]
medroxalol [who-dd]
SCHEMBL120537
5-[2-[[3-(1,3-benzodioxol-5-yl)-1-methylpropyl]amino]-1-hydroxyethyl]salicylamide
(1r,2r)-fmoc-2-aminocyclopentanecarboxylicacid
DTXSID30866550
Q15409395
rmi 81968;rmi-81968;rmi81968
MS-26010
CS-0021752
HY-101656

Research Excerpts

Overview

Medroxalol hydrochloride is an antihypertensive agent with beta 1 adrenergic cardiac blocking properties, and beta 2 and some alpha 1 vasodilating activity.

ExcerptReferenceRelevance
"Medroxalol is a new antihypertensive agent that is presently undergoing clinical trial. "( Cardiovascular properties of medroxalol, a new antihypertensive drug.
Cheng, HC; Dage, RC; Woodward, JK,
)
1.87
"Medroxalol hydrochloride is an antihypertensive agent with beta 1 adrenergic cardiac blocking properties, and beta 2 and some alpha 1 vasodilating activity. "( Induction of uterine leiomyomas in mice by medroxalol and prevention by propranolol.
Cheng, HC; Gibson, JP; Sells, DM; Yuh, L, 1987
)
1.98

Actions

ExcerptReferenceRelevance
"Medroxalol did not produce any evidence of a tumorigenic effect in the Long Evans rat, but graying of pigmented hair was noted at 250 and 500 mg/kg/day and is probably related to melanin binding of the drug."( Carcinogenicity studies with medroxalol hydrochloride in rats and mice.
Gibson, JP; Sells, DM, 1987
)
1.29

Pharmacokinetics

ExcerptReferenceRelevance
" For oral medroxalol the clinical pharmacokinetic parameters were a terminal elimination half-life (t 1/2,Z) of 15."( Comparison of the clinical pharmacokinetics and concentration-effect relationships for medroxalol and labetalol.
Elliott, HL; Meredith, PA; Reid, JL; Sumner, DJ, 1984
)
0.89
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35

Compound-Compound Interactions

ExcerptReferenceRelevance
" It is concluded that medroxalol combined with hydrochlorothiazide constituted a potent and safe antihypertensive therapy for the duration of the present study."( Medroxalol combined with hydrochlorothiazide in the treatment of hypertension.
Alexander, N; Maronde, RF; Valasquez, M; Vlachakis, ND, 1983
)
2.02

Bioavailability

ExcerptReferenceRelevance
" Bioavailability estimated from AUC was 27."( Kinetics of medroxalol, a beta- and alpha-adrenoceptor antagonist.
Alken, RG; Cheymol, G; Haegele, KD; Jaillon, P; Koch-Weser, J; Schechter, PJ, 1983
)
0.64
" Absolute bioavailability estimated from plasma AUC was 54 per cent for the solution and 38 per cent for the tablet, and the relative bioavailability from the tablet was 71 per cent."( Bioavailability of medroxalol in man.
Keeley, FJ; Okerholm, RA; Weiner, DL,
)
0.46

Dosage Studied

ExcerptRelevanceReference
"05) only at the lowest dosage (50 mg/kg/day)."( Carcinogenicity studies with medroxalol hydrochloride in rats and mice.
Gibson, JP; Sells, DM, 1987
)
0.56
" Isoproterenol (ISP) and neosynephrine (NSP) dose-response curves were recorded before the first dose and after each injection in both group."( [Hemodynamic effects of medroxalol in the anesthetized dog. Relation between adrenolytic properties and plasma concentration].
Biour, M; Cheymol, G; Haegele, K; Heckle, J; Juliard, JM; Weissenburger, J,
)
0.44
" The ratios of beta 1- to alpha 1-adrenoceptor antagonism as calculated from the relative shifts of the isoprenaline and phenylephrine dose-response curves, were 3 to 1 for labetalol and about 7 to 1 for medroxalol."( Comparison of medroxalol and labetalol, drugs with combined alpha- and beta-adrenoceptor antagonist properties.
Elliott, HL; McLean, K; Meredith, PA; Reid, JL; Sumner, DJ, 1984
)
0.82
"(1) When incremental infusions of drugs that increase blood pressure are given to human subjects to assess "pressor responsiveness," only the lower part of the sigmoid dose-response curve can be obtained."( Analysis of the pressor dose response.
Elliott, HL; Reid, JL; Sumner, DJ, 1982
)
0.26
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
salicylamides
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (22)

TimeframeStudies, This Drug (%)All Drugs %
pre-199019 (86.36)18.7374
1990's2 (9.09)18.2507
2000's1 (4.55)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 22.15

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index22.15 (24.57)
Research Supply Index3.53 (2.92)
Research Growth Index4.03 (4.65)
Search Engine Demand Index23.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (22.15)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (6.45%)5.53%
Reviews2 (6.45%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other27 (87.10%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]